Stojdl Lab, 02 Sep 2015 #Cancer patients with low baseline levels of TcR diversity achieved no clinical benefit with ipilimumab. http://bit.ly/1eeEIda…
Stojdl Lab, 29 Jun 2015 #Cancer patients with a greater baseline TCR diversity have better outcomes after anti-CTLA4 immunotherapy. http://bit.ly/1eeEId…